- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07778927
Effects of Goat Milk Formula on Gastrointestinal Comfort and Growth in Infants
A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Goat Milk Formula on Gastrointestinal Comfort, Behavioral Status, and Early Growth and Development in Infants
Infant gastrointestinal discomfort is common in early life and can affect feeding, sleep, and overall well-being. Goat milk formula, due to its unique protein composition and smaller fat globules, may be easier to digest and potentially improve gastrointestinal tolerance in infants.
This study is a multicenter, randomized, controlled trial designed to evaluate the effects of goat milk formula compared with standard cow milk formula in infants aged 0-5 months with gastrointestinal discomfort. The study will assess improvements in gastrointestinal symptoms, overall comfort, behavioral status, and early growth and development, as well as explore potential changes in gut microbiota and intestinal inflammation.
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Xinqiong Wang
- Numer telefonu: 021-64370045
- E-mail: wangxq1983@126.com
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Infants aged 0 to 5 months at enrollment
- Full-term birth (gestational age ≥37 weeks)
- Birth weight ≥2500 g
- Infants with symptoms of gastrointestinal discomfort (e.g., abdominal distension, excessive crying, regurgitation, or feeding intolerance)
- Parents or legal guardians able and willing to provide written informed consent and comply with study procedures
Exclusion Criteria:
- Infants with known or suspected organic gastrointestinal diseases (e.g., congenital malformations, Hirschsprung disease)
- History of severe perinatal complications or significant systemic diseases
- Known or suspected cow's milk protein allergy or other food allergies
- Use of antibiotics, probiotics, or other medications that may affect gastrointestinal function within 2 weeks prior to enrollment
- Participation in another clinical study within the past 3 months
- Any condition that, in the investigator's judgment, may interfere with study participation or outcome assessment For the reference cohort: healthy breastfed infants without significant gastrointestinal symptoms
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Goat Milk Formula Group
Infants in this group will be fed with goat milk-based infant formula and receive feeding and care guidance during the study period.
|
Infants will receive goat milk-based formula as their primary feeding during the intervention period, according to standard feeding practices.
|
|
Aktywny komparator: Cow Milk Formula Group
Infants in this group will continue to receive standard cow milk-based infant formula and receive feeding and care guidance during the study period.
|
Infants will receive standard cow milk-based formula as their primary feeding during the intervention period, according to routine feeding practices.
|
|
Brak interwencji: Healthy breastfeeding
No feeding intervention will be performed; only fecal samples and clinical data will be collected.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall Response Rate Based on Infant Composite Comfort Score (ICCS) at Day 14
Ramy czasowe: Baseline to Day 14
|
The overall response rate is defined as the proportion of participants in each group showing a ≥30% improvement in ICCS from baseline to Day 14. ICCS is a composite measure combining gastrointestinal symptom burden and behavioral state, with total scores ranging from 0 to 30.
Higher scores indicate better overall comfort (better outcome).
Response is categorized as: Markedly Effective (improvement ≥50%), Effective (improvement ≥30% to <50%), and Ineffective (improvement <30% or worsening).
The overall response rate is calculated as (Markedly Effective + Effective) / Total Cases × 100%.
|
Baseline to Day 14
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Gastrointestinal Symptom Burden Score
Ramy czasowe: Baseline to Day 28
|
Change in gastrointestinal symptom burden score from baseline to Day 28, assessed using the Infant Gastrointestinal Symptom Assessment Scale.
The scale ranges from 0 to 15, with higher scores indicating greater symptom burden (worse outcome).
|
Baseline to Day 28
|
|
Resolution Rate of Individual Gastrointestinal Symptoms
Ramy czasowe: Day 28
|
Proportion of infants with complete resolution of individual gastrointestinal symptoms (e.g., abdominal distension, crying, vomiting) by Day 28.
|
Day 28
|
|
Change in Daily Sleep Duration
Ramy czasowe: Baseline to Day 28
|
Change in total daily sleep duration (minutes) based on caregiver-recorded 24-hour infant behavior diary.
|
Baseline to Day 28
|
|
Change in Daily Awake and Content Time
Ramy czasowe: Baseline to Day 28
|
Change in total daily duration of awake and content state as reported by caregivers.
|
Baseline to Day 28
|
|
Change in Parent-Reported Infant Comfort/Feeding Experience
Ramy czasowe: Baseline to Day 28
|
Change from baseline to Day 28 in parent-reported infant comfort experience, assessed using the following instrument: Parenting Feeding and Nurturing Experience Questionnaire total score. This questionnaire consists of 5 items, each scored from 1 to 5, giving a total score range of 5 to 25. Higher scores indicate a more positive parenting and feeding experience (better outcome). |
Baseline to Day 28
|
|
Change in Parent-Reported Infant Feeding Experience
Ramy czasowe: Baseline to Day 28
|
Change from baseline to Day 28 in parent-reported infant feeding experience, assessed using the following instrument: Visual Analogue Scale (VAS) scores for parent-perceived infant overall comfort, feeding smoothness, and maternal anxiety. Each VAS item ranges from 0 to 10. For all three items, higher scores indicate better outcomes (i.e., more comfort, smoother feeding, and less anxiety). |
Baseline to Day 28
|
|
Change in Weight-for-Age Z-Score
Ramy czasowe: Baseline to Day 28
|
Change in weight-for-age Z-score from baseline to Day 28.
Weight is measured in kilograms (kg) using a calibrated electronic infant scale.
The Z-score is a continuous variable (standard deviation units relative to the WHO child growth standard), with a typical clinical range of -3 to +3.
Higher Z-scores indicate greater weight for age, generally reflecting better growth outcomes in this population.
|
Baseline to Day 28
|
|
Change in Head Circumference-for-Age Z-Score
Ramy czasowe: Baseline to Day 28
|
Change in head circumference-for-age Z-score from baseline to Day 28.
Head circumference is measured in centimeters (cm) using a non-stretchable measuring tape.
The Z-score is a continuous variable (standard deviation units relative to the WHO child growth standard), with a typical clinical range of -3 to +3.
Higher Z-scores indicate greater head circumference for age, reflecting appropriate brain and cranial growth.
|
Baseline to Day 28
|
|
Change in Length-for-Age Z-Score
Ramy czasowe: Baseline to Day 28
|
Change in length-for-age Z-score from baseline to Day 28.
Length is measured in centimeters (cm) using a standard infant length measurement board.
The Z-score is a continuous variable (standard deviation units relative to the WHO child growth standard), with a typical clinical range of -3 to +3.
Higher Z-scores indicate greater length for age, generally reflecting better growth outcomes in this population.
|
Baseline to Day 28
|
|
Changes in Gut Microbiota Composition
Ramy czasowe: Baseline and Week 4
|
Changes in gut microbiota composition, including relative abundance of key bacterial taxa, assessed by 16S rRNA sequencing of stool samples.
|
Baseline and Week 4
|
|
Change in Fecal Calprotectin Levels
Ramy czasowe: Baseline and Week 4
|
Change in fecal calprotectin concentration as a marker of intestinal inflammation.
|
Baseline and Week 4
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- GFC2026
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .